Skip to main content

Theseus Pharmaceuticals, Inc. (THRX)

NASDAQ: THRX · IEX Real-Time Price · USD
16.01 -0.05 (-0.31%)
Oct 27, 2021 12:35 PM EDT - Market open
Market Cap600.87M
Revenue (ttm)n/a
Net Income (ttm)-15.60M
Shares Out37.53M
EPS (ttm)-0.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume86,114
Open16.00
Previous Close16.06
Day's Range15.86 - 16.14
52-Week Range13.71 - 24.54
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About THRX

Theseus Pharmaceuticals is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Our development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. Resistance mutations limit the efficacy of existing targeted therapies by rendering tumor cells unresponsive to drugs, and therefore present a critical challenge in cancer treatment today. Our goal is to dev...

IndustryBiotechnology
IPO DateOct 7, 2021
CEOTimothy P. Clackson, Ph.D.
Employees13
Stock ExchangeNASDAQ
Ticker SymbolTHRX
Full Company Profile

Financial Performance

Financial Statements

News

Theseus Pharmaceuticals Announces Pricing of Initial Public Offering

Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery,...

2 weeks ago - PRNewswire

Theseus Pharmaceuticals IPO Registration Document (S-1)

Theseus Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC